CRTX

Cortexyme, Inc. [CRTX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

CRTX Stock Summary

In the News

CRTX Financial details

Company Rating
-
Market Cap
70.45M
Income
-149.93M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
55
Optionable
No
Shortable
Yes
Earnings
08 Aug 2022
P/E
-1654.01
Forward P/E
-
PEG
-236.35
P/S
-
P/B
567.65
P/C
-
P/FCF
-4.38
Quick Ratio
15.91
Current Ratio
16.7
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-4.47
EPS next Y
-
EPS next Q
-
EPS this Y
14.83%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-99.93%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-32%
ROE
-35%
ROC
-0.34%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
-
52W High
-
52W Low
-
RSI
58
Rel Volume
-
Avg Volume
-
Volume
272.21K
Perf Week
99%
Perf Month
178.37%
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
1.39583
-
-
Volatility
0.36%, 0.22%
Prev Close
105.26%
Price
1.95
Change
101.03%

Something similar

Top by Market Cap
ABEA.DE
AMZN
FXAIX
TL0.DE
META
Same Sector
BDX
IBAB.BR
VFRM
BGNE
GLYC
Check Those
SJR-B.TO
ECV.DE
8118.T
LEUR.L
PDYPF
Similar Market Cap
MBX.TO
EVX
EAH.L
CACG
GIFI

Company Profile

Healthcare Biotechnology
  • Market Capitalization 70.45M
  • Employee 55
  • CEO Ms. Casey Lynch
  • Headquarters South San Francisco,CALIFORNIA,US
  • IPO Date 2019-05-09
  • Website https://www.cortexyme.com

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.